Titan Biotech Ltd (TITANBIO) — shareholding pattern, promoter holding, financials and share price
About Titan Biotech Ltd (TITANBIO)
Titan Biotech Ltd operates in the Specialty Chemicals industry, within the Chemicals sector. It trades on the NSE as TITANBIO and on the BSE under scrip code 524717. Its ISIN is INE150C01029.
Incorporated in 1992, Titan Biotech Ltd manufacturer and exporter of the Biological products [1]
Titan Biotech Ltd. specializes in manufacturing biological peptones, extracts, and dehydrated culture media to support the growth of microorganisms crucial for diagnostics, vaccines, and pharmaceuticals.
The company uses animal and vegetable components to convert them into peptones, which become core sources for culture media, utilized broadly in healthcare and microbiological research.
Listed peers in Specialty Chemicals: Nitta Gelatin India Ltd, S H Kelkar & Company Ltd, Vidhi Specialty Food Ingredients Ltd, Paushak Ltd, Indokem Ltd, Platinum Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹402 a share on 10 Jul 2026, Titan Biotech Ltd (TITANBIO) was valued at a price-to-earnings ratio of 60.51x against an industry P/E of 45.11x and a price-to-book of 10.83x on a book value of ₹37.13 per share as of Mar 2025. Solomo computes return on equity of 17.89% and return on capital employed of 25.03% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 60.51x
- Industry P/E
- 45.11x
- P/B
- 10.83x
- EPS (TTM)
- ₹6.64
- Book value / share
- ₹37.13
- ROE
- 17.89%
- ROCE
- 25.03%
- ROA
- 15.71%
- Debt / equity
- 0.02x
- Dividend yield
- 0.5%
- EBITDA margin
- 21.35%
- 52-week range
- ₹390.75 – ₹407
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Titan Biotech Ltd (TITANBIO) reported revenue of ₹206 crore, net profit of ₹30 crore and earnings per share of ₹7.23. That compares with revenue of ₹156 crore and net profit of ₹22 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹48.83 crore and net profit ₹6.73 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 124 | 144 | 164 | 156 | 206 |
| Net profit (₹ cr) | 22 | 25 | 25 | 22 | 30 |
| EPS (₹) | 5.25 | 6.01 | 6.02 | 5.21 | 7.23 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 13.84% | 17.63% | 8.19% | -4.64% |
| Profit growth | 30.00% | 24.12% | -5.55% | -22.78% |
| Stock price CAGR | 51% | 43% | 102% | 360% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 55.78% of Titan Biotech Ltd (TITANBIO) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.01%. Market capitalisation was ₹1,661 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Investor Education And Protection Fund Author 9.51%, Manish Goel 2.8%, Titan Biotech Limited Unclaimed Suspense Dema 2.36%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 55.78% | - | - | 0.01% | 44.22% |
| Mar 2026 | 55.78% | - | - | 0.03% | 44.22% |
| Dec 2025 | 55.78% | - | - | 0.03% | 44.22% |
| Sep 2025 | 55.78% | - | - | 0.03% | 44.22% |
| Jun 2025 | 55.88% | - | - | 0.03% | 44.12% |
| Mar 2025 | 55.88% | - | - | 0.01% | 44.12% |
| Dec 2024 | 55.88% | - | - | - | 44.12% |
| Sep 2024 | 55.88% | - | - | - | 44.12% |